Detailed Narrative
Robust Q1 FY25 Performance Driven by Formulations
Granules India reported a strong Q1 FY25, with revenue growing 20% YoY to ₹11,799 million and EBITDA increasing 89% YoY to ₹2,593 million. The EBITDA margin expanded significantly to 22% from 13.9% in Q1 FY24. This growth was primarily driven by the formulations segment, which now contributes 76% to overall sales, a substantial increase from 65% in FY24 and 50% in FY23.
Strategic Shift to New Products and US Market Traction
The company's strategy to diversify beyond its legacy five products is yielding results, with new products contributing 35% to Q1 revenue, up from 15% in FY23. The US market remains a key growth driver, with North America sales growing almost 45% in Q1 FY25, partly due to a lower base from a cyber incident in the prior year. Management expects this region to continue growing in excess of 20%, fueled by new launches and increased market share.
Paracetamol Headwinds and Expected Recovery
The Paracetamol market is currently in a 'very bad shape' due to high inventory levels across Europe and the US, impacting the company's European sales, which were down 35% in INR terms. Management anticipates Paracetamol will not contribute significantly for at least another two quarters, leading to 'very marginal growth in topline' in the near term. However, they expect Paracetamol to contribute positively to revenue and profitability from next year (FY26).
CZRO Project Faces Teething Issues and Infrastructure Delays
The ambitious Granules CZRO (green molecule platform) project has encountered 'teething issues' at its pilot plant and delays in infrastructure creation in Kakinada, including power supply discussions with NTPC. While the main plant equipment has been ordered, management is proceeding cautiously, emphasizing a stage-gate approach to the ₹2,000 crore investment. Validation of at least 3 molecules on the enzymes and manufacturing technology platform is still targeted for Q3 FY25.
Expanding Product Pipeline and Capacity for Future Growth
Granules is actively building its product pipeline in oncology and the CNS/ADHD segments, with oncology product launches expected to commence in FY26. The company plans to file a couple of oncology products in the next few quarters and is investing in a new oncology API manufacturing facility, expected to be completed in 12 months from September. Formulation capacity is being ramped up, with the Gagillapur facility at almost 100% utilization and the new GLS site expected to reach 1.2-1.3 billion capacity by year-end, with an additional 2-3 billion capacity coming online next year.
Financial Health and Margin Outlook
The company's net debt decreased by ₹481 million to ₹7,941 million. Gross margins are expected to be sustainable around 58-59%, with an aspiration to maintain around 60%. EBITDA margins are targeted to improve year-on-year, staying above 20% and potentially settling around 25% in a year's time. R&D spend increased to ₹620 million in Q1 FY25 and is expected to rise further in subsequent quarters, supporting the robust product pipeline.
Cash Conversion Cycle and Price Erosion
The cash-to-cash cycle increased to 183 days from 161 days at the beginning of the year, attributed to new launches and Red Sea issues. Management expects this to normalize to FY24 levels as Red Sea impacts subside. US price erosion has stabilized to a 'mid-single digit' level, indicating a more stable pricing environment in the key market.